Step 1 topics → Psychiatry → Typical (First-Generation) Antipsychotics

Typical (First-Generation) Antipsychotics

USMLE Step 1 trap: Inverts the side-effect profiles of high-potency versus low-potency typical antipsychotics. High-potency typicals (e.g., haloperidol) cause more EPS and less sedation/anticholinergic/hypotensive effects; low-potency typicals (e.g., chlorpromazine) cause more sedation, anticholinergic effects, and orthostatic hypotension.

Typical (first-generation) antipsychotics are among the highest-yield drug classes on USMLE Step 1. They work by blocking D2 dopamine receptors, but that single mechanism plays out across four distinct brain pathways — and the exam exploits every one of them. You need to know not just that these drugs cause side effects, but which drug causes which side effect, why, and when. The core mechanism question is almost never 'what does haloperidol do?' — it's 'a patient develops sustained muscle contraction of the neck two days after starting haloperidol — what's the mechanism and treatment?' That's application, not recall.

The trickiest part of this topic is keeping potency profiles straight. Students routinely invert high- versus low-potency side effects, assuming 'more potent' means 'more of every side effect.' It doesn't. High-potency agents like haloperidol bind D2 tightly with little affinity for muscarinic, histamine, or alpha receptors — so you get more EPS but fewer anticholinergic, sedating, and hypotensive effects. Low-potency agents like chlorpromazine are pharmacologically dirty: they block D2 but also hit muscarinic, H1, and alpha-1 receptors, producing sedation, dry mouth/urinary retention, and orthostatic hypotension. Step 1 loves to give you a side effect and ask you to identify the agent, or give you an agent and ask which complication is most likely.

The extrapyramidal side effects (EPS) are tested relentlessly, and the timeline is a favorite trap. Acute dystonia comes first — hours to days. Akathisia and pseudoparkinsonism follow within days to weeks. Tardive dyskinesia is the late complication, appearing after months to years of use and notoriously difficult to reverse. USMLE Step 1 questions will give you a timeline clue and expect you to name the correct EPS subtype and its treatment. Don't mix up NMS with serotonin syndrome — they look superficially similar but have distinct features, different onsets, and completely different treatments.

From real student decks
78%have cards covering this topic
57%have mature cards
2median lapses in 14 days

Common misconceptions

Common mistake
Wrong: High-potency antipsychotics cause more metabolic and anticholinergic side effects than low-potency agents.
Right: High-potency typicals (e.g., haloperidol) cause more EPS and less sedation/anticholinergic/hypotensive effects; low-potency typicals (e.g., chlorpromazine) cause more sedation, anticholinergic effects, and orthostatic hypotension.
Potency refers specifically to D2 receptor affinity — it does not mean the drug affects all receptor systems more. High-potency agents like haloperidol are selective enough that they cause intense D2-mediated effects (EPS, hyperprolactinemia) but spare histamine, muscarinic, and alpha-1 receptors, so sedation and anticholinergic effects are minimal. Low-potency agents like chlorpromazine are receptor-promiscuous: they block H1 (sedation), muscarinic M1 (dry mouth, constipation, urinary retention, blurry vision), and alpha-1 (orthostatic hypotension) in addition to D2. When the stem describes a patient with sedation and orthostatic hypotension, think low-potency; when it describes acute dystonia, think high-potency.
Common mistake
Wrong: Tardive dyskinesia appears early in treatment and acute dystonia appears late.
Right: Acute dystonia occurs within hours to days, akathisia and parkinsonism within days to weeks, and tardive dyskinesia after months to years of treatment.
The EPS timeline follows a predictable sequence that the exam uses as a discriminating clue. Acute dystonia is the earliest — sustained involuntary muscle contractions (torticollis, oculogyric crisis) within hours to a day or two of starting or increasing the drug. Akathisia (subjective restlessness) and pseudoparkinsonism (bradykinesia, pill-rolling tremor, masked facies) emerge over days to weeks. Tardive dyskinesia is the late-appearing, often irreversible syndrome of stereotyped orofacial or choreiform movements after months to years of exposure. If a vignette says 'two days after starting' — think acute dystonia, not tardive dyskinesia.
Common mistake
Wrong: NMS and serotonin syndrome are clinically identical and treated the same way.
Right: NMS features lead-pipe rigidity, hyperthermia, autonomic instability, and elevated CK with a slow onset over days (treated with dantrolene/bromocriptine); serotonin syndrome features clonus/hyperreflexia, diaphoresis, and rapid onset (treated with cyproheptadine).
NMS and serotonin syndrome are both hyperthermic emergencies but have mechanistically opposite causes and distinct physical findings. NMS results from dopamine receptor blockade and presents with lead-pipe (uniform) rigidity, hyperthermia, autonomic instability, and markedly elevated CK; onset is gradual over 24–72 hours. Serotonin syndrome results from excess serotonergic activity and features clonus, hyperreflexia, and diaphoresis — not lead-pipe rigidity — with rapid onset (hours). Treatment differs completely: NMS requires stopping the antipsychotic, dantrolene (muscle relaxant), and bromocriptine (D2 agonist to restore dopaminergic tone); serotonin syndrome is treated with cyproheptadine (5-HT2A antagonist). Mixing up these treatments on the exam is a high-cost error.
Common mistake
Gap: Missing knowledge of pathway-specific consequences of D2 blockade beyond antipsychotic effect
D2 blockade in the mesolimbic pathway reduces positive symptoms, but blockade in the nigrostriatal pathway causes EPS, tuberoinfundibular pathway causes hyperprolactinemia, and mesocortical pathway worsens negative symptoms.
D2 blockade doesn't stay confined to the limbic system — it hits all four major dopaminergic pathways simultaneously. The mesolimbic pathway is where you want blockade: it reduces positive symptoms (hallucinations, delusions). The nigrostriatal pathway is where EPS come from: blockade here mimics the dopamine loss of Parkinson's disease. The tuberoinfundibular pathway normally keeps prolactin suppressed; block it and prolactin rises, causing galactorrhea, amenorrhea, and gynecomastia. The mesocortical pathway normally supports cognition and motivation; blocking it can worsen negative symptoms (flat affect, alogia, avolition). Understanding this four-pathway framework lets you reason through any D2-related question rather than memorizing disconnected facts.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Mechanism: Know that D2 blockade in the mesolimbic pathway reduces positive symptoms, but D2 blockade in the nigrostriatal pathway causes EPS, in the tuberoinfundibular pathway causes hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), and in the mesocortical pathway can worsen negative symptoms — the exam tests all four pathways.
  2. Potency profiles: Given a clinical scenario or a specific agent (haloperidol vs. chlorpromazine vs. thioridazine), identify which side effects are most likely — high-potency typicals cause more EPS; low-potency typicals cause more sedation, anticholinergic effects, and orthostatic hypotension.
  3. EPS timeline and treatment: Match each EPS category to its typical onset — acute dystonia (hours–days, treat with benztropine or diphenhydramine), akathisia (days–weeks, treat with beta-blockers or benzodiazepines), pseudoparkinsonism (days–weeks, treat with benztropine), and tardive dyskinesia (months–years, treat by stopping the drug or switching to clozapine/quetiapine, or using valbenazine/deutetrabenazine).
  4. NMS: Recognize the clinical triad of hyperthermia, severe lead-pipe rigidity, and autonomic instability with elevated CK after antipsychotic use; distinguish from serotonin syndrome by onset, rigidity pattern, and treatment (dantrolene + bromocriptine, not cyproheptadine).

Can you avoid these mistakes?

A 24-year-old man with schizophrenia is started on haloperidol. Three days later he presents with his eyes deviated upward and he cannot look down voluntarily. What is this reaction called, what is the mechanism, and how do you treat it?
A patient on chlorpromazine complains of dry mouth, constipation, and feels lightheaded when standing. A patient on haloperidol develops a shuffling gait and pill-rolling tremor. Which side effects are expected for each drug, and why do the profiles differ despite both being D2 blockers?
After 18 months on fluphenazine, a patient develops repetitive lip-smacking and tongue movements. Meanwhile, a different patient develops hyperthermia, lead-pipe rigidity, and an elevated CK one week after a dose increase. Name both conditions, distinguish them, and outline the treatment approach for the second patient.
A medical student says: 'Blocking D2 receptors in the brain should reduce dopamine effects everywhere, which is why these drugs cause both fewer positive symptoms AND fewer negative symptoms.' What is wrong with this reasoning, and which pathways explain why typical antipsychotics can actually worsen certain aspects of schizophrenia?

Related topics

Schizophrenia Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar I Disorder Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →